Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clinton Yam

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
Nature Cancer|October 17, 2022
Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complexYu-Yi Chu, Mei-Kuang Chen, Yongkun Wei, et al.
JCO Precision Oncology|December 18, 2025
Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast CancerBeatriz E Adrada, Mary S Guirguis, Lei Huo, et al.
Radiology. Imaging Cancer|July 28, 2023
A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast CancerKen-Pin Hwang, Nabil A Elshafeey, Aikaterini Kotrotsou, et al.
Scientific Reports|July 11, 2024
Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerRania M Mohamed, Bikash Panthi, Beatriz E Adrada, et al.
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
Frontiers in Oncology|November 9, 2023
Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerBikash Panthi, Rania M Mohamed, Beatriz E Adrada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast CancerClinton Yam, Nour Abuhadra, Ryan Sun, et al.
Scientific Reports|January 20, 2023
Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRIZijian Zhou, Beatriz E Adrada, Rosalind P Candelaria, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|December 12, 2023
Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIsZijian Zhou, Beatriz E Adrada, Rosalind P Candelaria, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
Nature Cancer|October 17, 2022
Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complexYu-Yi Chu, Mei-Kuang Chen, Yongkun Wei, et al.
JCO Precision Oncology|December 18, 2025
Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast CancerBeatriz E Adrada, Mary S Guirguis, Lei Huo, et al.
Radiology. Imaging Cancer|July 28, 2023
A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast CancerKen-Pin Hwang, Nabil A Elshafeey, Aikaterini Kotrotsou, et al.
Scientific Reports|July 11, 2024
Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerRania M Mohamed, Bikash Panthi, Beatriz E Adrada, et al.
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
Frontiers in Oncology|November 9, 2023
Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerBikash Panthi, Rania M Mohamed, Beatriz E Adrada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast CancerClinton Yam, Nour Abuhadra, Ryan Sun, et al.
Scientific Reports|January 20, 2023
Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRIZijian Zhou, Beatriz E Adrada, Rosalind P Candelaria, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|December 12, 2023
Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIsZijian Zhou, Beatriz E Adrada, Rosalind P Candelaria, et al.
Pageof 7